FDA Advances Drug Repurposing to Address Unmet Medical Needs

FDA Seeks Public Input on Drug Repurposing for Unmet Needs

On May 11, 2026, the U.S. Food and Drug Administration announced it is soliciting public input on efforts to advance drug repurposing to address unmet medical needs across various diseases and conditions. This initiative aims to accelerate treatment availability by identifying new uses for FDA-approved drugs, leveraging existing knowledge, including a drug's safety profile. The agency is particularly focused on new uses to treat chronic or rare diseases and seeks information on priority disease areas, potential drug candidates with existing or preliminary data, and innovative approaches, as well as barriers to development, especially where commercial incentives are limited.

• The FDA's initiative emphasizes drug repurposing as a critical strategy to address the lack of effective treatment options for many patients. By identifying new indications or populations for existing FDA-approved drugs, the agency aims to expedite the availability of treatments, capitalizing on established safety profiles and scientific data to reduce development timelines and costs.
• The FDA is actively seeking comprehensive input from patients, clinicians, researchers, and other stakeholders. This includes identifying priority disease areas with significant unmet needs, such as metabolic, neurodegenerative, women’s/men’s health, substance use disorders, and rare diseases. The agency also requests information on drug candidates with sufficient existing evidence or promising preliminary clinical/preclinical data, and insights into barriers limiting repurposing efforts.
• This effort builds upon established authorities and initiatives like the Best Pharmaceuticals for Children Act, the MODERN Labeling Act of 2020, and Project Renewal, which update drug labeling based on scientific evidence. Furthermore, it aligns with the September 2025 Make Our Children Healthy Again strategy and involves collaborations with federal partners such as the National Institutes of Health and the Centers for Medicare and Medicaid Services to refine approaches and facilitate repurposing opportunities.

Addressing the Limitations in Current Unmet Medical Needs Treatments

Global health disparities represent a fundamental challenge in addressing unmet medical needs, with low- and middle-income countries (LMICs) facing severe systemic limitations. These countries experience critical shortages in infrastructure, financial resources, regulatory frameworks, and healthcare workforce, resulting in treatment gaps exceeding 75% for conditions like mental health disorders. In stark contrast, high-income countries (HICs) demonstrate significantly better resource allocation, with mental health budget shares of 6.1%-11.3% compared to less than 1% in LMICs, and psychiatrist densities of 11.8-14.6 per 100,000 population versus less than 1 per 100,000 in LMICs. The strong negative correlation between treatment gap and budget share (r = -0.82, p < .001) underscores how economic capacity and political commitment directly impact healthcare system effectiveness.

Even in well-resourced healthcare settings with access to advanced therapeutics, significant treatment inadequacies persist. Greek Crohn's disease patients exemplify this challenge, where despite 83.7% receiving biological or small molecule therapies, substantial disease burden continues with 73.1% reporting impaired quality of life, 30.9% experiencing reduced work productivity, and 46.1% presenting moderate-to-severe depressive symptoms. Notably, 76.3% of patients on advanced therapies still reported impaired quality of life, with 30.9% of these patients being in clinical remission, demonstrating that current treatment paradigms may not adequately address the full spectrum of patient needs beyond traditional clinical endpoints.

The pharmaceutical development landscape faces additional complexity due to fundamental misalignment in how unmet medical needs are conceptualized across stakeholders. Regulators emphasize disease severity and clinical evidence, patients and clinicians prioritize quality of life improvements, while health technology assessment bodies focus on comparative benefit and long-term outcomes. These divergent perspectives create inconsistencies in development strategies, trial design, and regulatory planning, ultimately hampering the systematic identification and resolution of true unmet medical needs. This lack of consensus necessitates clearer yet adaptable criteria to enable earlier and more consistent stakeholder alignment throughout the drug development process.

Identifying Priority Disease Areas for Repurposed Therapies

Recent literature has identified three distinct population groups experiencing significant unmet medical needs, with research focusing on social determinants of health, healthcare access disparities, and precision medicine gaps. These studies reveal critical care delivery challenges across pediatric, Indigenous, and rheumatologic patient populations that require targeted interventions.

• Pediatric surgery patients face substantial unmet social needs, with 17.1% of 1,410 screened patients testing positive for at least one social determinant of health issue, yet only 5.8% received referrals for assistance despite high rates of virtual care access problems (24.9%) and food insecurity (22.3%)

• Urban-dwelling Indigenous Taiwanese adults continue experiencing significant health disparities despite universal healthcare coverage, with everyday discrimination creating barriers to care that are fully mediated by perceived access obstacles and resulting in lower patient activation and weaker provider relationships

• Rheumatoid arthritis patients represent a highly heterogeneous population requiring risk-stratified therapeutic approaches, with unmet needs spanning treatment-refractory disease management, precision medicine implementation barriers, and the need for individualized strategies accounting for infection risk, cardiovascular disease, malignancy, and reproductive considerations

• Social determinants screening gaps in pediatric surgical settings reveal a disconnect between identified needs and service delivery, with only 34% of families screening positive for unmet needs actually requesting assistance, highlighting implementation challenges in translating screening to intervention

• Discrimination-mediated healthcare barriers among Indigenous populations demonstrate how systemic inequities translate into measurable care quality deficits, with effects on unmet needs entirely explained by perceived access barriers rather than direct discrimination effects

• Precision medicine implementation challenges in rheumatology include limited access to local biospecimens, outcome definition complexities, and trial design barriers that prevent optimal therapeutic selection and monitoring strategies to minimize overtreatment risks

How Repurposing Will Shape the Unmet Medical Needs Landscape

The treatment landscape for unmet medical needs has undergone significant transformation over the past five years, driven by advances in molecular biology and genomics that have enabled the development of highly targeted therapies. Recent scientific breakthroughs have facilitated the creation of advanced therapy medicinal products and RNA-based treatments, representing a new frontier in precision medicine for rare diseases. Between 2000 and 2021, the European Medicines Agency assigned orphan designation to over 1,900 medicines, though clinical evidence at marketing authorization remains limited due to small target populations and recruitment challenges. Looking ahead, projections indicate that by 2033, approximately 45 new product approvals for pediatric-onset rare diseases will emerge from current pipelines, representing a 14% growth in annual treated patients and generating an incremental $10.7 billion in drug revenues.

Despite these therapeutic advances, substantial gaps persist in the treatment ecosystem. Real-world evidence reveals that 95% of pediatric-onset rare diseases are projected to remain without approved treatments over the next decade, as the rate of newly identified rare diseases continues to outpace therapeutic development. Current treatment outcomes demonstrate ongoing challenges, exemplified by data from Greece showing that among Crohn's disease patients receiving advanced therapies, 76.3% still reported impaired quality of life, with 30.9% experiencing this burden despite achieving clinical remission. These findings underscore that advanced therapeutic availability does not automatically translate to optimal patient outcomes.

Regulatory and access innovations have emerged as critical components of landscape evolution, with novel trial methodologies and policy frameworks reshaping development paradigms. Clinical trial design has evolved to incorporate difference-in-differences methods and synthetic control approaches, enabling more robust evaluation of long-term treatment effects in rare disease populations. China has implemented comprehensive orphan drug policies including six-year data protection periods, tax incentives, and coverage expansion to 95 orphan drugs in their national insurance catalog as of March 2024. However, access inequalities persist globally, particularly in Latin America and the Caribbean, where regulatory approval often fails to translate into timely coverage due to high costs and fragmented health system arrangements, highlighting the ongoing need for integrated approaches to address both therapeutic development and equitable access.

FDA's Repurposing Push: A New Era for Unmet Needs

The U.S. Food and Drug Administration's recent call for public input on advancing drug repurposing is more than a procedural announcement; it represents a strategic recognition of a powerful, yet often underutilized, pathway to address critical unmet medical needs. In an era where traditional drug development faces escalating costs, protracted timelines, and diminishing success rates, repurposing offers a compelling alternative. By identifying novel uses for already approved drugs, we can leverage their established safety profiles, significantly reducing the time and financial investment typically required for new drug discovery. This approach has demonstrated a higher success rate for FDA approval compared to de novo drug development, making it an attractive avenue for innovation.

This initiative holds particular promise for the millions affected by rare and chronic diseases, where the commercial viability of developing entirely new treatments is often limited. Repurposing can unlock therapeutic options for these underserved populations, offering hope where little existed. However, realizing this potential requires navigating several complexities. The commercial landscape for repurposed drugs can be challenging, as limited intellectual property protection and the looming threat of generic entry can dampen incentives for the extensive clinical trials needed to validate new indications. Furthermore, the regulatory pathways for repositioning can be more intricate than for simple reformulations, demanding a nuanced understanding and harmonized approach.

The FDA's focus on innovative strategies, including the integration of artificial intelligence and real-world data, points towards a future where computational tools will play a pivotal role in systematically identifying and validating repurposing candidates. This signals a clear imperative for pharmaceutical companies to invest in advanced data analytics and foster public-private collaborations. By proactively engaging with this FDA initiative, stakeholders can help shape a framework that not only streamlines regulatory processes but also creates sustainable incentives, ultimately accelerating the delivery of life-changing treatments to patients who need them most.